Pharma BD Deal Intelligence
Boehringer Ingelheim GmbH / NBE Therapeutics
2020 · Acquisition/Merger · $1.5B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
28
Did not work — the deal failed to deliver.
Boehringer Ingelheim acquired NBE Therapeutics for $1.5B for breast and lung cancer treatments.
Key facts
- Announced Dec 10, 2020
- Closed Feb 28, 2021
- Deal value $1.5B
- Deal type Acquisition/Merger
- Therapeutic area Oncology
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals